NKPL 66

Drug Profile

NKPL 66

Alternative Names: NKPL-66

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Acasti Pharma
  • Class Antihyperlipidaemics; Phospholipids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 26 Oct 2016 Acasti Pharma has patent protection for NKPL 66 in USA
  • 25 May 2016 Acasti Pharma completes enrolment in a Pharmacokinetic trial in Hypertriglyceridaemia in USA
  • 01 Dec 2015 NKPL 66 is available for licensing as of 01 Dec 2015. http://www.acastipharma.com/en/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top